{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:12:21Z","timestamp":1788361941429,"version":"build-2803163510"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biotechnol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12033-025-01464-y","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T09:10:03Z","timestamp":1751274603000},"page":"1597-1608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transforming Hemophilia Management: Lessons from Gene Therapy Clinical Trials"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3554-1750","authenticated-orcid":false,"given":"Md Sadique","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudasir","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita Joshi","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumel","family":"Ashique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumna","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Jakhmola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"7534","key":"1464_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature13864","volume":"517","author":"A Barzel","year":"2015","unstructured":"Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M., & Kay, M. A. (2015). Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature, 517(7534), 360\u2013364. https:\/\/doi.org\/10.1038\/nature13864","journal-title":"Nature"},{"issue":"R1","key":"1464_CR2","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","volume":"28","author":"P Batty","year":"2019","unstructured":"Batty, P., & Lillicrap, D. (2019). Advances and challenges for hemophilia gene therapy. Human Molecular Genetics, 28(R1), R95-r101. https:\/\/doi.org\/10.1093\/hmg\/ddz157","journal-title":"Human Molecular Genetics"},{"key":"1464_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.omtm.2020.10.013","volume":"19","author":"W Cao","year":"2020","unstructured":"Cao, W., Dong, B., Horling, F., Firrman, J. A., Lengler, J., Klugmann, M., de la Rosa, M., Wu, W., Wang, Q., Wei, H., Moore, A. R., Roberts, S. A., Booth, C. J., Hoellriegl, W., Li, D., Konkle, B., Miao, C., Reipert, B. M., Scheiflinger, F., \u2026 Xiao, W. (2020). Minimal essential human factor VIII alterations enhance secretion and gene therapy efficiency. Molecular Therapy Methods and Clinical Development, 19, 486\u2013495. https:\/\/doi.org\/10.1016\/j.omtm.2020.10.013","journal-title":"Molecular Therapy Methods and Clinical Development"},{"issue":"9","key":"1464_CR4","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","volume":"104","author":"G Castaman","year":"2019","unstructured":"Castaman, G., & Matino, D. (2019). Hemophilia A and B: Molecular and clinical similarities and differences. Haematologica, 104(9), 1702\u20131709. https:\/\/doi.org\/10.3324\/haematol.2019.221093","journal-title":"Haematologica"},{"issue":"2","key":"1464_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/jci79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., & Venditti, C. P. (2015). Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. The Journal of Clinical Investigation, 125(2), 870\u2013880. https:\/\/doi.org\/10.1172\/jci79213","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"1464_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/hae.15121","volume":"31","author":"J Chapin","year":"2025","unstructured":"Chapin, J., \u00c1lvarez Rom\u00e1n, M. T., Ayash-Rashkovsky, M., Diogo, D., Kenniston, J., Lopez-Jaime, F. J., Maggiore, C., Mingot-Castellano, M. E., Rajavel, K., Rauch, A., & Susen, S. (2025). A phase 1\/2 safety and efficacy study of TAK-754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials. Haemophilia, 31(1), 108\u2013117.","journal-title":"Haemophilia"},{"key":"1464_CR7","unstructured":"Chapin, J., Ayash-Rashkovsky, M., Kenniston, J., Wagoner, M., & Wang, Q. (2022). A translational analysis of immune components in peripheral blood from severe hemophilia A patients treated with TAK-754, an AAV8 vector with a codon-optimized B-domain\u2013deleted factor VIII transgene. Presentation PB0211. ISTH Congress"},{"key":"1464_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biom14070854","author":"N Chernyi","year":"2024","unstructured":"Chernyi, N., Gavrilova, D., Saruhanyan, M., Oloruntimehin, E. S., Karabelsky, A., Bezsonov, E., & Malogolovkin, A. (2024). Recent advances in gene therapy for hemophilia: projecting the perspectives. Biomolecules. https:\/\/doi.org\/10.3390\/biom14070854","journal-title":"Biomolecules"},{"issue":"3","key":"1464_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa2119913","volume":"387","author":"P Chowdary","year":"2022","unstructured":"Chowdary, P., Shapiro, S., Makris, M., Evans, G., Boyce, S., Talks, K., Dolan, G., Reiss, U., Phillips, M., Riddell, A., Peralta, M. R., Quaye, M., Patch, D. W., Tuddenham, E., Dane, A., Watiss\u00e9e, M., Long, A., & Nathwani, A. (2022). Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B. New England Journal of Medicine, 387(3), 237\u2013247. https:\/\/doi.org\/10.1056\/NEJMoa2119913","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"1464_CR10","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","volume":"11","author":"M Coppens","year":"2024","unstructured":"Coppens, M., Pipe, S. W., Miesbach, W., Astermark, J., Recht, M., van der Valk, P., Ewenstein, B., Pinachyan, K., Galante, N., & Le Quellec, S. (2024). Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. The Lancet Haematology, 11(4), e265\u2013e275.","journal-title":"The Lancet Haematology"},{"issue":"1","key":"1464_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-0044-1796629","volume":"51","author":"A Coppola","year":"2025","unstructured":"Coppola, A., Zani, M., Quintavalle, G., Focosi, D., & Franchini, M. (2025). The evolution of hemophilia pharmacological treatments and therapeutic targets at the turn of the third millennium. Seminars in Thrombosis and Hemostasis, 51(1), 10\u201317. https:\/\/doi.org\/10.1055\/s-0044-1796629","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"13","key":"1464_CR12","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMcibr1600347","volume":"374","author":"AM Davidoff","year":"2016","unstructured":"Davidoff, A. M., & Nathwani, A. C. (2016). Genetic targeting of the albumin locus to treat hemophilia. New England Journal of Medicine, 374(13), 1288\u20131290. https:\/\/doi.org\/10.1056\/NEJMcibr1600347","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"1464_CR13","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","volume":"8","author":"A Donsante","year":"2001","unstructured":"Donsante, A., Vogler, C., Muzyczka, N., Crawford, J. M., Barker, J., Flotte, T., Campbell-Thompson, M., Daly, T., & Sands, M. S. (2001). Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Therapy, 8(17), 1343\u20131346. https:\/\/doi.org\/10.1038\/sj.gt.3301541","journal-title":"Gene Therapy"},{"issue":"1","key":"1464_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2011.104","volume":"23","author":"P Fagone","year":"2012","unstructured":"Fagone, P., Wright, J. F., Nathwani, A. C., Nienhuis, A. W., Davidoff, A. M., & Gray, J. T. (2012). Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods. Human Gene Therapy Methods, 23(1), 1\u20137. https:\/\/doi.org\/10.1089\/hgtb.2011.104","journal-title":"Human Gene Therapy Methods"},{"key":"1464_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16121582","author":"C Feng","year":"2024","unstructured":"Feng, C., Wang, Y., Xu, J., Zheng, Y., Zhou, W., Wang, Y., & Luo, C. (2024). Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16121582","journal-title":"Pharmaceutics"},{"issue":"4","key":"1464_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","volume":"28","author":"S Fong","year":"2022","unstructured":"Fong, S., Yates, B., Sihn, C. R., Mattis, A. N., Mitchell, N., Liu, S., Russell, C. B., Kim, B., Lawal, A., Rangarajan, S., Lester, W., Bunting, S., Pierce, G. F., Pasi, K. J., & Wong, W. Y. (2022). Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nature Medicine, 28(4), 789\u2013797. https:\/\/doi.org\/10.1038\/s41591-022-01751-0","journal-title":"Nature Medicine"},{"issue":"21","key":"1464_CR17","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George, L. A., Monahan, P. E., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Rasko, J. E. J., Recht, M., Samelson-Jones, B. J., MacDougall, A., Jaworski, K., Noble, R., Curran, M., Kuranda, K., Mingozzi, F., Chang, T., Reape, K. Z., Anguela, X. M., & High, K. A. (2021). Multiyear factor VIII expression after AAV gene transfer for hemophilia A. New England Journal of Medicine, 385(21), 1961\u20131973. https:\/\/doi.org\/10.1056\/NEJMoa2104205","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"1464_CR18","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., Chen, Y., Anguela, X. M., Kuranda, K., Mingozzi, F., & High, K. A. (2020). Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Molecular Therapy, 28(9), 2073\u20132082. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.001","journal-title":"Molecular Therapy"},{"issue":"23","key":"1464_CR19","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., McGuinn, C. E., Ragni, M. V., Luk, A. Y., Hui, D., Wright, J. F., Chen, Y., Liu, Y., Wachtel, K., Winters, A., \u2026 High, K. A. (2017). Hemophilia B gene therapy with a high-specific-activity factor IX variant. New England Journal of Medicine, 377(23), 2215\u20132227. https:\/\/doi.org\/10.1056\/NEJMoa1708538","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"1464_CR20","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/jth.12958","volume":"13","author":"AC Goodeve","year":"2015","unstructured":"Goodeve, A. C. (2015). Hemophilia B: Molecular pathogenesis and mutation analysis. Journal of Thrombosis and Haemostasis, 13(7), 1184\u20131195. https:\/\/doi.org\/10.1111\/jth.12958","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"1464_CR21","first-page":"S383","volume":"102","author":"K High","year":"2004","unstructured":"High, K., Manno, C., Sabatino, D., Hutchison, S., Dake, M., Razavi, M., Kaye, R., Aruda, V., Herzog, R., & Rustagi, P. (2004). Immune responses to AAV and to factor IX in a phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B. Molecular Therapy, 102, S383\u2013S384.","journal-title":"Molecular Therapy"},{"issue":"13","key":"1464_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.21037\/atm-21-747","volume":"9","author":"I Hotea","year":"2021","unstructured":"Hotea, I., Brinza, M., Blag, C., Zimta, A. A., Dirzu, N., Burzo, C., Rus, I., Apostu, D., Benea, H., Marian, M., Mester, A., Pasca, S., Iluta, S., Teodorescu, P., Jitaru, C., Zdrenghea, M., Bojan, A., Torok-Vistai, T., Niculescu, R., \u2026 Coriu, D. (2021). Current therapeutic approaches in the management of haemophilia\u2014A consensus view by the Romanian Society of Hematology. Annals of Translational Medicine, 9(13), 1091. https:\/\/doi.org\/10.21037\/atm-21-747","journal-title":"Annals of Translational Medicine"},{"key":"1464_CR23","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1182\/blood-2018-99-119116","volume":"132","author":"S Hurst","year":"2018","unstructured":"Hurst, S., Warren, C., & Pasi, K. J. (2018). Gene therapy in hemophilia: An assessment of hematologists\u2019 knowledge gaps and attitudes. Blood, 132, 3485.","journal-title":"Blood"},{"key":"1464_CR24","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232388661250430062849","author":"MS Hussain","year":"2025","unstructured":"Hussain, M. S., Khan, G., & Gupta, G. (2025). Advances in gene therapy for X-linked myotubular myopathy: Current progress and future challenges. Current Gene Therapy. https:\/\/doi.org\/10.2174\/0115665232388661250430062849","journal-title":"Current Gene Therapy"},{"key":"1464_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/life14121568","author":"IM Iurea","year":"2024","unstructured":"Iurea, I. M., Severin, E., & Matei, A. (2024). Transforming hemophilia A care: Insights into new therapeutic options. Life (Basel). https:\/\/doi.org\/10.3390\/life14121568","journal-title":"Life (Basel)"},{"issue":"12","key":"1464_CR26","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","volume":"30","author":"A Kapelanski-Lamoureux","year":"2022","unstructured":"Kapelanski-Lamoureux, A., Chen, Z., Gao, Z. H., Deng, R., Lazaris, A., Lebeaupin, C., Giles, L., Malhotra, J., Yong, J., Zou, C., de Jong, Y. P., Metrakos, P., Herzog, R. W., & Kaufman, R. J. (2022). Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma. Molecular Therapy, 30(12), 3542\u20133551. https:\/\/doi.org\/10.1016\/j.ymthe.2022.10.004","journal-title":"Molecular Therapy"},{"key":"1464_CR27","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128386290250507101412","author":"G Khan","year":"2025","unstructured":"Khan, G., & Hussain, M. S. (2025). Expanding the potential of gene therapy for Duchenne muscular dystrophy. Current Pharmaceutical Design. https:\/\/doi.org\/10.2174\/0113816128386290250507101412","journal-title":"Current Pharmaceutical Design"},{"issue":"6","key":"1464_CR28","first-page":"763","volume":"137","author":"BA Konkle","year":"2021","unstructured":"Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W., Samulski, R. J., Bilic, I., & De La Rosa, M. (2021). BAX 335 hemophilia B gene therapy clinical trial results: Potential impact of CpG sequences on gene expression. Blood, The Journal of the American Society of Hematology, 137(6), 763\u2013774.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"1464_CR29","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/mtm.2016.6","volume":"3","author":"S Kyostio-Moore","year":"2016","unstructured":"Kyostio-Moore, S., Berthelette, P., Piraino, S., Sookdeo, C., Nambiar, B., Jackson, R., Burnham, B., O\u2019Riordan, C. R., Cheng, S. H., & Armentano, D. (2016). The impact of minimally oversized adeno-associated viral vectors encoding human factor VIII on vector potency in vivo. Molecular Therapy Methods & Clinical Development, 3, 16006. https:\/\/doi.org\/10.1038\/mtm.2016.6","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"1464_CR30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2024-208486","volume":"144","author":"AD Leavitt","year":"2024","unstructured":"Leavitt, A. D., Kavakli, K., Frenzel, L., Antmen, A. B., Ozelo, M., Matino, D., Alzahrani, H., Konkle, B. A., Pipe, S. W., & Teitel, J. M. (2024). Efficacy and safety of giroctocogene fitelparvovec in adults with moderately severe to severe hemophilia \u0391: Primary analysis results from the phase 3 \u0391FFINE gene therapy trial. Blood, 144, 1053.","journal-title":"Blood"},{"issue":"9","key":"1464_CR31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1182\/blood.2022018971","volume":"143","author":"AD Leavitt","year":"2024","unstructured":"Leavitt, A. D., Konkle, B. A., Stine, K. C., Visweshwar, N., Harrington, T. J., Giermasz, A., Arkin, S., Fang, A., Plonski, F., & Yver, A. (2024). Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study. Blood, 143(9), 796\u2013806.","journal-title":"Blood"},{"issue":"8","key":"1464_CR32","doi-asserted-by":"publisher","first-page":"102615","DOI":"10.1016\/j.rpth.2024.102615","volume":"8","author":"AD Leavitt","year":"2024","unstructured":"Leavitt, A. D., Mahlangu, J., Raheja, P., Symington, E., Quon, D. V., Giermasz, A., Fern\u00e1ndez, M. F. L., Kenet, G., Lowe, G., & Key, N. S. (2024). Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. Research and Practice in Thrombosis and Haemostasis, 8(8), 102615.","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"6","key":"1464_CR33","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1109\/tcbb.2024.3459870","volume":"21","author":"C Li","year":"2024","unstructured":"Li, C., Wang, H., Wen, Y., Yin, R., Zeng, X., & Li, K. (2024). GenoM7GNet: An efficient N(7)-methylguanosine site prediction approach based on a nucleotide language model. IEEE\/ACM Transactions on Computational Biology and Bioinformatics, 21(6), 2258\u20132268. https:\/\/doi.org\/10.1109\/tcbb.2024.3459870","journal-title":"IEEE\/ACM Transactions on Computational Biology and Bioinformatics"},{"issue":"7","key":"1464_CR34","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.stem.2024.04.021","volume":"31","author":"S Li","year":"2024","unstructured":"Li, S., Ling, S., Wang, D., Wang, X., Hao, F., Yin, L., Yuan, Z., Liu, L., Zhang, L., Li, Y., Chen, Y., Luo, L., Dai, Y., Zhang, L., Chen, L., Deng, D., Tang, W., Zhang, S., Wang, S., & Cai, Y. (2024). Modified lentiviral globin gene therapy for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia: A single-center, single-arm pilot trial. Cell Stem Cell, 31(7), 961-973.e968. https:\/\/doi.org\/10.1016\/j.stem.2024.04.021","journal-title":"Cell Stem Cell"},{"key":"1464_CR35","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.2147\/ijgm.S483505","volume":"17","author":"H Liu","year":"2024","unstructured":"Liu, H., Tang, Y., Zhou, Q., Zhang, J., Li, X., Gu, H., Hu, B., & Li, Y. (2024). The interrelation of blood urea nitrogen-to-albumin ratio with three-month clinical outcomes in acute ischemic stroke cases: a secondary analytical exploration derived from a prospective cohort study. International Journal of General Medicine, 17, 5333\u20135347. https:\/\/doi.org\/10.2147\/ijgm.S483505","journal-title":"International Journal of General Medicine"},{"issue":"7","key":"1464_CR36","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","volume":"32","author":"BR Long","year":"2024","unstructured":"Long, B. R., Robinson, T. M., Day, J. R., Yu, H., Lau, K., Imtiaz, U., Patton, K. S., de Hart, G., Henshaw, J., & Agarwal, S. (2024). Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A. Molecular Therapy, 32(7), 2052\u20132063.","journal-title":"Molecular Therapy"},{"issue":"8","key":"1464_CR37","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","volume":"101","author":"CS Manno","year":"2003","unstructured":"Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., Couto, L. B., Leonard, D. G., Johnson, F. A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A. W., Kay, M. A., High, K. A., & Glader, B. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 101(8), 2963\u20132972. https:\/\/doi.org\/10.1182\/blood-2002-10-3296","journal-title":"Blood"},{"key":"1464_CR38","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2002.1.1","author":"PM Mannucci","year":"2002","unstructured":"Mannucci, P. M. (2002). Hemophilia and related bleeding disorders: a story of dismay and success. Hematology\u2014American Society of Hematology Education Program. https:\/\/doi.org\/10.1182\/asheducation-2002.1.1","journal-title":"Hematology\u2014American Society of Hematology Education Program"},{"issue":"8","key":"1464_CR39","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.jtha.2023.04.030","volume":"21","author":"W Miesbach","year":"2023","unstructured":"Miesbach, W., Foster, G. R., & Peyvandi, F. (2023). \u201cLiver-related aspects of gene therapy for hemophilia: Need for collaborations with hepatologists\u201d: Reply. Journal of Thrombosis and Haemostasis, 21(8), 2307\u20132308. https:\/\/doi.org\/10.1016\/j.jtha.2023.04.030","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"1464_CR40","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","volume":"131","author":"W Miesbach","year":"2018","unstructured":"Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schw\u00e4ble, J., Bonig, H., Seifried, E., Cattaneo, F., Meyer, C., & Leebeek, F. W. G. (2018). Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood, 131(9), 1022\u20131031. https:\/\/doi.org\/10.1182\/blood-2017-09-804419","journal-title":"Blood"},{"issue":"4","key":"1464_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/hae.13769","volume":"25","author":"W Miesbach","year":"2019","unstructured":"Miesbach, W., O\u2019Mahony, B., Key, N. S., & Makris, M. (2019). How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia, 25(4), 545\u2013557. https:\/\/doi.org\/10.1111\/hae.13769","journal-title":"Haemophilia"},{"key":"1464_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7325","author":"M Milani","year":"2019","unstructured":"Milani, M., Annoni, A., Moalli, F., Liu, T., Cesana, D., Calabria, A., Bartolaccini, S., Biffi, M., Russo, F., Visigalli, I., Raimondi, A., Patarroyo-White, S., Drager, D., Cristofori, P., Ayuso, E., Montini, E., Peters, R., Iannacone, M., Cantore, A., & Naldini, L. (2019). Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.aav7325","journal-title":"Science Translational Medicine"},{"issue":"7","key":"1464_CR43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ng1380","volume":"36","author":"DG Miller","year":"2004","unstructured":"Miller, D. G., Petek, L. M., & Russell, D. W. (2004). Adeno-associated virus vectors integrate at chromosome breakage sites. Nature Genetics, 36(7), 767\u2013773. https:\/\/doi.org\/10.1038\/ng1380","journal-title":"Nature Genetics"},{"issue":"4","key":"1464_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2174\/156652311796150354","volume":"11","author":"F Mingozzi","year":"2011","unstructured":"Mingozzi, F., & High, K. A. (2011). Immune responses to AAV in clinical trials. Current Gene Therapy, 11(4), 321\u2013330. https:\/\/doi.org\/10.2174\/156652311796150354","journal-title":"Current Gene Therapy"},{"issue":"5","key":"1464_CR45","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.v97.5.1258","volume":"97","author":"AC Nathwani","year":"2001","unstructured":"Nathwani, A. C., Davidoff, A., Hanawa, H., Zhou, J. F., Vanin, E. F., & Nienhuis, A. W. (2001). Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood, 97(5), 1258\u20131265. https:\/\/doi.org\/10.1182\/blood.v97.5.1258","journal-title":"Blood"},{"issue":"7","key":"1464_CR46","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","volume":"107","author":"AC Nathwani","year":"2006","unstructured":"Nathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., Mertens, K., & Davidoff, A. M. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 107(7), 2653\u20132661. https:\/\/doi.org\/10.1182\/blood-2005-10-4035","journal-title":"Blood"},{"key":"1464_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","volume":"132","author":"AC Nathwani","year":"2018","unstructured":"Nathwani, A. C., Reiss, U., Tuddenham, E., Chowdary, P., McIntosh, J., Riddell, A., Pie, J., Mahlangu, J. N., Recht, M., & Shen, Y.-M. (2018). Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer. Blood, 132, 491.","journal-title":"Blood"},{"issue":"21","key":"1464_CR48","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani, A. C., Reiss, U. M., Tuddenham, E. G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., Pie, J., Rangarajan, S., Bevan, D., Recht, M., Shen, Y. M., Halka, K. G., Basner-Tschakarjan, E., Mingozzi, F., \u2026 Davidoff, A. M. (2014). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. New England Journal of Medicine, 371(21), 1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa1407309","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"1464_CR49","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani, A. C., Tuddenham, E. G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., O\u2019Beirne, J., Smith, K., Pasi, J., Glader, B., Rustagi, P., Ng, C. Y., Kay, M. A., Zhou, J., Spence, Y., \u2026 Davidoff, A. M. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. New England Journal of Medicine, 365(25), 2357\u20132365. https:\/\/doi.org\/10.1056\/NEJMoa1108046","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"1464_CR50","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jtha.2023.04.012","volume":"21","author":"GN Nguyen","year":"2023","unstructured":"Nguyen, G. N., Lindgren, J. R., Seleme, M. C., Kafle, S., Zander, C. B., Zheng, X. L., & Sabatino, D. E. (2023). Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice. Journal of Thrombosis and Haemostasis, 21(8), 2101\u20132113. https:\/\/doi.org\/10.1016\/j.jtha.2023.04.012","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"1464_CR51","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","volume":"25","author":"AW Nienhuis","year":"2017","unstructured":"Nienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2017). Gene therapy for hemophilia. Molecular Therapy, 25(5), 1163\u20131167. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.033","journal-title":"Molecular Therapy"},{"issue":"9","key":"1464_CR52","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., Valente, N., Asikanius, E., Levy, G. G., Windyga, J., & Shima, M. (2017). Emicizumab prophylaxis in hemophilia A with inhibitors. New England Journal of Medicine, 377(9), 809\u2013818. https:\/\/doi.org\/10.1056\/NEJMoa1703068","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"1464_CR53","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo, M. C., Mahlangu, J., Pasi, K. J., Giermasz, A., Leavitt, A. D., Laffan, M., Symington, E., Quon, D. V., Wang, J. D., Peerlinck, K., Pipe, S. W., Madan, B., Key, N. S., Pierce, G. F., O\u2019Mahony, B., Kaczmarek, R., Henshaw, J., Lawal, A., Jayaram, K., \u2026 Kim, B. (2022). Valoctocogene roxaparvovec gene therapy for hemophilia A. New England Journal of Medicine, 386(11), 1013\u20131025. https:\/\/doi.org\/10.1056\/NEJMoa2113708","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"1464_CR54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., & Wong, W. Y. (2020). Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. New England Journal of Medicine, 382(1), 29\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1908490","journal-title":"New England Journal of Medicine"},{"issue":"10040","key":"1464_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0140-6736(15)01123-x","volume":"388","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F., Garagiola, I., & Young, G. (2016). The past and future of haemophilia: Diagnosis, treatments, and its complications. Lancet, 388(10040), 187\u2013197. https:\/\/doi.org\/10.1016\/s0140-6736(15)01123-x","journal-title":"Lancet"},{"issue":"1","key":"1464_CR56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/hae.14908","volume":"30","author":"G Pietu","year":"2024","unstructured":"Pietu, G., Giraud, N., Chamouard, V., Duport, G., Lienhart, A., & Dargaud, Y. (2024). Perspectives and perception of haemophilia gene therapy by French patients. Haemophilia, 30(1), 68\u201374. https:\/\/doi.org\/10.1111\/hae.14908","journal-title":"Haemophilia"},{"key":"1464_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2020-139803","volume":"136","author":"SW Pipe","year":"2020","unstructured":"Pipe, S. W., Ferrante, F., Reis, M., Wiegmann, S., Lange, C., Braun, M., & Michaels, L. A. (2020). First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A-BAY 2599023 has broad patient eligibility and stable and sustained long-term expression of FVIII. Blood, 136, 44\u201345.","journal-title":"Blood"},{"issue":"8","key":"1464_CR58","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe, S. W., Leebeek, F. W. G., Recht, M., Key, N. S., Castaman, G., Miesbach, W., Lattimore, S., Peerlinck, K., Van der Valk, P., Coppens, M., Kampmann, P., Meijer, K., O\u2019Connell, N., Pasi, K. J., Hart, D. P., Kazmi, R., Astermark, J., Hermans, C., Klamroth, R., \u2026 Monahan, P. E. (2023). Gene therapy with etranacogene dezaparvovec for hemophilia B. New England Journal of Medicine, 388(8), 706\u2013718. https:\/\/doi.org\/10.1056\/NEJMoa2211644","journal-title":"New England Journal of Medicine"},{"key":"1464_CR59","doi-asserted-by":"publisher","first-page":"LBA-6","DOI":"10.1182\/blood-2020-143560","volume":"136","author":"SW Pipe","year":"2020","unstructured":"Pipe, S. W., Recht, M., Key, N. S., Leebeek, F. W., Castaman, G., Lattimore, S. U., Van Der Valk, P., Peerlinck, K., Coppens, M., & O\u2019Connell, N. (2020). First data from the phase 3 HOPE-B gene therapy trial: efficacy and safety of etranacogene dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in adults with severe or moderate-severe hemophilia B treated irrespective of pre-existing anti-capsid neutralizing antibodies. Blood, 136, LBA-6.","journal-title":"Blood"},{"key":"1464_CR60","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1182\/blood-2021-148661","volume":"138","author":"SW Pipe","year":"2021","unstructured":"Pipe, S. W., Sheehan, J. P., Coppens, M., Eichler, H., Linardi, C., Wiegmann, S., Hay, C. R., & Lissitchkov, T. (2021). First-in-human dose-finding study of AAVhu37 vector-based gene therapy: BAY 2599023 has stable and sustained expression of FVIII over 2 years. Blood, 138, 3971.","journal-title":"Blood"},{"issue":"11","key":"1464_CR61","first-page":"832","volume":"109","author":"X Qiu","year":"1996","unstructured":"Qiu, X., Lu, D., Zhou, J., Wang, J., Yang, J., Meng, P., & Hsueh, J. L. (1996). Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients. Chinese Medical Journal (England), 109(11), 832\u2013839.","journal-title":"Chinese Medical Journal (England)"},{"issue":"26","key":"1464_CR62","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., & Pasi, K. J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. New England Journal of Medicine, 377(26), 2519\u20132530. https:\/\/doi.org\/10.1056\/NEJMoa1708483","journal-title":"New England Journal of Medicine"},{"key":"1464_CR63","doi-asserted-by":"publisher","first-page":"237437352311935","DOI":"10.1177\/23743735231193573","volume":"10","author":"E Rasul","year":"2023","unstructured":"Rasul, E., Hallock, R., Hellmann, M., Konduros, J., Pembroke, L., LeCleir, G., Malacan, J., & von Mackensen, S. (2023). Gene therapy in hemophilia: A transformational patient experience. Journal of Patient Experience, 10, 23743735231193572. https:\/\/doi.org\/10.1177\/23743735231193573","journal-title":"Journal of Patient Experience"},{"issue":"Suppl 3","key":"1464_CR64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/hae.14080","volume":"27","author":"UM Reiss","year":"2021","unstructured":"Reiss, U. M., Zhang, L., & Ohmori, T. (2021). Hemophilia gene therapy-New country initiatives. Haemophilia, 27(Suppl 3), 132\u2013141. https:\/\/doi.org\/10.1111\/hae.14080","journal-title":"Haemophilia"},{"issue":"23","key":"1464_CR65","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/nejm200106073442301","volume":"344","author":"DA Roth","year":"2001","unstructured":"Roth, D. A., Tawa, N. E., Jr., O\u2019Brien, J. M., Treco, D. A., & Selden, R. F. (2001). Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. New England Journal of Medicine, 344(23), 1735\u20131742. https:\/\/doi.org\/10.1056\/nejm200106073442301","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"1464_CR66","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","volume":"126","author":"R Sharma","year":"2015","unstructured":"Sharma, R., Anguela, X. M., Doyon, Y., Wechsler, T., DeKelver, R. C., Sproul, S., Paschon, D. E., Miller, J. C., Davidson, R. J., Shivak, D., Zhou, S., Rieders, J., Gregory, P. D., Holmes, M. C., Rebar, E. J., & High, K. A. (2015). In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood, 126(15), 1777\u20131784. https:\/\/doi.org\/10.1182\/blood-2014-12-615492","journal-title":"Blood"},{"key":"1464_CR67","doi-asserted-by":"publisher","DOI":"10.2174\/011871529x370285250323162851","author":"N Singla","year":"2025","unstructured":"Singla, N., Rathod, A., Hussain, M. S., Goyal, K., Roopashree, R., Bansal, P., Mishra, S., Prasad, G. V. S., Ali, H., & Gupta, G. (2025). Hematohidrosis: A rare case of blood sweating. Cardiovascular & Hematological Disorders-Drug Targets. https:\/\/doi.org\/10.2174\/011871529x370285250323162851","journal-title":"Cardiovascular & Hematological Disorders-Drug Targets"},{"issue":"5","key":"1464_CR68","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1056\/NEJMoa2410597","volume":"392","author":"A Srivastava","year":"2025","unstructured":"Srivastava, A., Abraham, A., Aboobacker, F., Singh, G., Geevar, T., Kulkarni, U., Selvarajan, S., Korula, A., Dave, R. G., & Shankar, M. (2025). Lentiviral gene therapy with CD34+ hematopoietic cells for hemophilia A. New England Journal of Medicine, 392(5), 450\u2013457.","journal-title":"New England Journal of Medicine"},{"key":"1464_CR69","doi-asserted-by":"publisher","unstructured":"Srivastava, A., Santagostino, E., Dougall, A., Kitchen, S., Sutherland, M., Pipe, S. W., Carcao, M., Mahlangu, J., Ragni, M. V., Windyga, J., Llin\u00e1s, A., Goddard, N. J., Mohan, R., Poonnoose, P. M., Feldman, B. M., Lewis, S. Z., van den Berg, H. M., & Pierce, G. F. (2020). WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 26, 1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046","DOI":"10.1111\/hae.14046"},{"key":"1464_CR70","doi-asserted-by":"publisher","first-page":"113392","DOI":"10.1016\/j.intimp.2024.113392","volume":"144","author":"DY Sun","year":"2025","unstructured":"Sun, D. Y., Hu, Y. J., Li, X., Peng, J., Dai, Z. J., & Wang, S. (2025). Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. International Immunopharmacology, 144, 113392. https:\/\/doi.org\/10.1016\/j.intimp.2024.113392","journal-title":"International Immunopharmacology"},{"issue":"5","key":"1464_CR71","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/hae.15071","volume":"30","author":"E Symington","year":"2024","unstructured":"Symington, E., Rangarajan, S., Lester, W., Madan, B., Pierce, G. F., Raheja, P., Millar, C., Osmond, D., Li, M., & Robinson, T. M. (2024). Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A. Haemophilia, 30(5), 1138\u20131147.","journal-title":"Haemophilia"},{"key":"1464_CR72","doi-asserted-by":"publisher","first-page":"263300402110588","DOI":"10.1177\/26330040211058896","volume":"2","author":"CD Thornburg","year":"2021","unstructured":"Thornburg, C. D. (2021). Etranacogene dezaparvovec for hemophilia B gene therapy. Therapeutic Advances in Rare Disease, 2, 26330040211058896. https:\/\/doi.org\/10.1177\/26330040211058896","journal-title":"Therapeutic Advances in Rare Disease"},{"issue":"1","key":"1464_CR73","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0029-1214151","volume":"35","author":"NO Viiala","year":"2009","unstructured":"Viiala, N. O., Larsen, S. R., & Rasko, J. E. (2009). Gene therapy for hemophilia: Clinical trials and technical tribulations. Seminars in Thrombosis and Hemostasis, 35(1), 81\u201392. https:\/\/doi.org\/10.1055\/s-0029-1214151","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"1464_CR74","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1182\/blood-2021-148651","volume":"138","author":"N Visweshwar","year":"2021","unstructured":"Visweshwar, N., Harrington, T. J., Leavitt, A. D., Konkle, B. A., Giermasz, A., Stine, K., Rupon, J., Di Russo, G., Tseng, L.-J., de Angeles Resa, M., Ganne, F., Agathon, D., Plonski, F., Rouy, D., Cockroft, B. M., Fang, A., & Arkin, S. (2021). Updated results of the alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia a. Blood, 138, 564. https:\/\/doi.org\/10.1182\/blood-2021-148651","journal-title":"Blood"},{"issue":"21","key":"1464_CR75","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","volume":"3","author":"A Von Drygalski","year":"2019","unstructured":"Von Drygalski, A., Giermasz, A., Castaman, G., Key, N. S., Lattimore, S., Leebeek, F. W., Miesbach, W., Recht, M., Long, A., & Gut, R. (2019). Etranacogene dezaparvovec (AMT-061 phase 2b): Normal\/near normal FIX activity and bleed cessation in hemophilia B. Blood advances, 3(21), 3241\u20133247.","journal-title":"Blood advances"},{"issue":"7","key":"1464_CR76","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/17474086.2016.1182859","volume":"9","author":"P Ward","year":"2016","unstructured":"Ward, P., & Walsh, C. E. (2016). Current and future prospects for hemophilia gene therapy. Expert Review of Hematology, 9(7), 649\u2013659. https:\/\/doi.org\/10.1080\/17474086.2016.1182859","journal-title":"Expert Review of Hematology"},{"issue":"7","key":"1464_CR77","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","volume":"9","author":"F Xue","year":"2022","unstructured":"Xue, F., Li, H., Wu, X., Liu, W., Zhang, F., Tang, D., Chen, Y., Wang, W., Chi, Y., & Zheng, J. (2022). Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: A single-centre, single-arm, phase 1, pilot trial. The Lancet Haematology, 9(7), e504\u2013e513.","journal-title":"The Lancet Haematology"},{"key":"1464_CR78","doi-asserted-by":"publisher","first-page":"914347","DOI":"10.3389\/fphar.2022.914347","volume":"13","author":"H Yang","year":"2022","unstructured":"Yang, H., He, C., Bi, Y., Zhu, X., Deng, D., Ran, T., & Ji, X. (2022). Synergistic effect of VEGF and SDF-1\u03b1 in endothelial progenitor cells and vascular smooth muscle cells. Frontiers in Pharmacology, 13, 914347. https:\/\/doi.org\/10.3389\/fphar.2022.914347","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"1464_CR79","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s42003-024-06488-9","volume":"7","author":"Z Yang","year":"2024","unstructured":"Yang, Z., Liu, X., Xu, H., Teschendorff, A. E., Xu, L., Li, J., Fu, M., Liu, J., Zhou, H., Wang, Y., Zhang, L., He, Y., Lv, K., & Yang, H. (2024). Integrative analysis of genomic and epigenomic regulation reveals miRNA mediated tumor heterogeneity and immune evasion in lower grade glioma. Communications Biology, 7(1), 824. https:\/\/doi.org\/10.1038\/s42003-024-06488-9","journal-title":"Communications Biology"},{"issue":"9","key":"1464_CR80","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.stem.2024.06.007","volume":"31","author":"C Zhou","year":"2024","unstructured":"Zhou, C., Kuang, M., Tao, Y., Wang, J., Luo, Y., Fu, Y., Chen, Z., Liu, Y., Li, Z., Wu, W., Wang, L., Dou, Y., Wang, J., & Hou, Y. (2024). Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening. Cell Stem Cell, 31(9), 1359-1375.e1358. https:\/\/doi.org\/10.1016\/j.stem.2024.06.007","journal-title":"Cell Stem Cell"}],"container-title":["Molecular Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-025-01464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12033-025-01464-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-025-01464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T04:01:15Z","timestamp":1775448075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12033-025-01464-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1464"],"URL":"https:\/\/doi.org\/10.1007\/s12033-025-01464-y","relation":{},"ISSN":["1073-6085","1559-0305"],"issn-type":[{"value":"1073-6085","type":"print"},{"value":"1559-0305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest. Generative AI and AI-assisted technologies in the writing process: during the preparation of this work, the author(s) used ChatGPT to correct the grammatical and typographical errors in the manuscript. All authors have approved the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}